Recombinant TIMP1 treatment increased the invasion area, whereas anti-TIMP1 antibody exposure blocked the invasion of fibroblasts into the matrix, implying that TIMP1 provoked MM progression by activating and/or converting BM fibroblasts. This evidence concerns the gene TIMP1 and Miyoshi myopathy.